Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 7589.

https://doi.org/10.1182/blood-2024-210586

Published: 2024

Journal Articles

Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study

Jacqueline F. Wang, Jihao Zhou, Reema K. Tawfiq, Han W. Tun, Javier L. Munoz, Jonas Paludo, Muhamad Alhaj Moustafa, Steven R. Hwang, Izel Okcu, Catherine S. Diefenbach, Jia Ruan, Peter Martin, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang

Blood (2024) 144 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2024-204268

Published: 2024

Journal Articles

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 68.

https://doi.org/10.1182/blood-2024-208539

Published: 2024

Journal Articles

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2024-194601

Published: 2024

Journal Articles

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma

Yucai Wang, Han W. Tun, Betsy R. LaPlant, Rebecca L. King, Ivana N. Micallef, Madiha Iqbal, Allison C. Rosenthal, Stephen M. Ansell, Jose C. Villasboas Bisneto, Arushi Khurana, Gita Thanarajasingam, Thomas M. Habermann, Javier L. Munoz, Paul J. Hampel, Patrick B. Johnston, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2024) 144 (Supplement 1): 580.

https://doi.org/10.1182/blood-2024-200206

Published: 2024

Journal Articles

Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2024) 144 (Supplement 1): 2345.

https://doi.org/10.1182/blood-2024-210594

Published: 2024

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2023) 142 (Supplement 1): 3761.

https://doi.org/10.1182/blood-2023-188382

Published: 2023

Journal Articles

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Marc S. Hoffmann, Javier L. Munoz, Jason Westin, Theodoros Vassilakopoulos, Alejandro Martin Garcia-Sancho, Antonio Rueda Dominguez, Wojciech Jurczak, Su-Peng Yeh, Maria Bouzani, Argyrios Gkasiamis, Mark Kaplan, Arpankumar Patel, Floriane Boucaud, Ju Li, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4459.

https://doi.org/10.1182/blood-2023-174242

Published: 2023

Journal Articles

Treatment Pattern and Survival Outcome of Limited Stage Mantle Cell Lymphoma: A National Cancer Database Analysis in Pre-BTK Inhibitor Vs BTK Inhibitor Era

Jihao Zhou, Jacqueline F. Wang, Steven Ray Hwang, Jonas Paludo, Javier L. Munoz, David James Inwards, Allison C. Rosenthal, William Breen, Scott Lester, Stephen M Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang

Blood (2023) 142 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2023-177790

Published: 2023

Journal Articles

The Impact of Pre-Existing Autoimmune Disease on the Safety and Efficacy of CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2023-188155

Published: 2023

Journal Articles

A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group

Jacqueline F. Wang, Jihao Zhou, Steven R Hwang, Catherine S Diefenbach, Jia Ruan, Peter Martin, Jonas Paludo, Javier L. Munoz, Stephen M Ansell, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan, Grzegorz S. Nowakowski, Yucai Wang

Blood (2023) 142 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2023-179611

Published: 2023

Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Blood (2023) 142 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2023-173873

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Blood (2023) 142 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2023-189196

Published: 2023

Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2023) 142 (Supplement 1): 894.

https://doi.org/10.1182/blood-2023-174510

Published: 2023

Journal Articles

Exploring Regional Challenges and Solutions to Appropriate and Equitable Care for Patients with Chronic Lymphocytic Leukemia

Farrukh T. Awan, Javier L. Munoz, Amy Goodrich, Onyemaechi Okolo-Taku, Christopher D'Andrea, Alison Mayer Sachs, Ashley Lile, Rania Emara, Lilly Meier, Elana Plotkin, Leigh Boehmer

Blood (2023) 142 (Supplement 1): 7253.

https://doi.org/10.1182/blood-2023-179917

Published: 2023

Journal Articles

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, Patrick M. Reagan, David B. Miklos, Frederick L. Locke, Andre Goy, Caron A. Jacobson, Javier L. Munoz, Edouard Forcade, Max S. Topp, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Marie José Kersten, Michael L. Wang

Blood (2023) 142 (Supplement 1): 2120.

https://doi.org/10.1182/blood-2023-174681

Published: 2023

Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2023) 142 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2023-179868

Published: 2023

Journal Articles

Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Multicenter Analysis

Sowjanya Vuyyala, Andre De Menezes Silva Corraes, Megumi Bailey, Madiha Iqbal, Javier L. Munoz, Bradley Hunter, Radhika Bansal, Krish Patel, Mohamed A. Kharfan-Dabaja, Allison C. Rosenthal, Yucai Wang, Jonas Paludo, Patrick B Johnston, N. Nora Bennani, J. C. C. Villasboas, Urshila Durani, Stephen M Ansell, Yi Lin, Arushi Khurana

Blood (2023) 142 (Supplement 1): 6926.

https://doi.org/10.1182/blood-2023-188441

Published: 2023

NARROW

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma

Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Treatment Pattern and Survival Outcome of Limited Stage Mantle Cell Lymphoma: A National Cancer Database Analysis in Pre-BTK Inhibitor Vs BTK Inhibitor Era

The Impact of Pre-Existing Autoimmune Disease on the Safety and Efficacy of CAR T-Cell Therapy for Non-Hodgkin Lymphoma

A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Exploring Regional Challenges and Solutions to Appropriate and Equitable Care for Patients with Chronic Lymphocytic Leukemia

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Multicenter Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only